Dottikon ES Holding AG/Fr. DESN
1D1W1MYTD1Y5YMAX
Capital at risk
About Dottikon ES Holding AG
Dottikon ES Holding AG is a Swiss-based company specializing in the development and production of performance chemicals, primarily focusing on the pharmaceutical industry. The company is known for its hazardous reactions expertise, which supports its clients in drug development and production processes. Dottikon ES offers services and products including exclusive synthesis, process development, and related toll manufacturing. Headquartered in Dottikon, Switzerland, the company leverages its strategic positioning by focusing on safety, quality, and flexibility to meet specific customer needs in complex chemical reactions.
- Ticker
- Fr. DESN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 900
- Headquarters
- Dottikon, Switzerland
- Website
- dottikon.com
DESN Metrics
BasicAdvanced
CHF 3.6B
34.63
CHF 7.49
0.94
-
Price and volume
Market cap
CHF 3.6B
Beta
0.94
52-week high
CHF 396.00
52-week low
CHF 253.50
Average daily volume
4K
Financial strength
Current ratio
3.555
Quick ratio
2.097
Long term debt to equity
0.119
Total debt to equity
0.119
Interest coverage (TTM)
87.17%
Profitability
EBITDA (TTM)
151.055
Gross margin (TTM)
61.25%
Net profit margin (TTM)
23.55%
Operating margin (TTM)
27.36%
Effective tax rate (TTM)
12.22%
Revenue per employee (TTM)
CHF 490,000
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
9.92%
Valuation
Price to earnings (TTM)
34.627
Price to revenue (TTM)
8.155
Price to book
3.26
Price to tangible book (TTM)
3.27
Price to free cash flow (TTM)
122.46
Free cash flow yield (TTM)
0.82%
Free cash flow per share (TTM)
2.119
Growth
Revenue change (TTM)
12.03%
Earnings per share change (TTM)
-1.91%
3-year revenue growth (CAGR)
10.52%
10-year revenue growth (CAGR)
13.57%
3-year earnings per share growth (CAGR)
5.67%
10-year earnings per share growth (CAGR)
20.68%
Bulls say / Bears say
Dottikon says demand for small-molecule cGMP capacity should outstrip supply for the next five to eight years, helped by more complex medicines, Western supply-chain relocation and high-volume treatments such as obesity drugs. (Dottikon ES)
The capacity investment is beginning to become usable: the new 100-cubic-metre production plant and API drying plant have been approved, all four first-phase drying lines are operational, and the first line of the new large-scale plant is running. (Dottikon ES, DCAT Value Chain Insights)
The shares recently reached a 15-month low, while ZKB forecasts revenue growth of 22.8% in FY27 and 27.5% in FY28. If the new plants ramp as expected, that gap between weak sentiment and projected growth could support a recovery. (cash)
FY26 sales rose 11.2%, but net income fell 1.9% and the EBITDA margin dropped from 36.5% to 34.6%. Higher staffing, materials and depreciation on new plants are already weighing on returns. (Dottikon ES)
Visibility on the next year is limited: management gave no specific FY27 outlook, while analysts described the results as disappointing and said the timing of capacity ramp-ups makes their revenue impact difficult to predict. (finanzen.ch, cash)
The expansion is capital-heavy: Dottikon plans roughly CHF1 billion of investment across five years and is again retaining profit rather than paying a dividend. It also warns that widespread US API capacity expansion could create a major surplus from 2035. (Dottikon ES, cash)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
DESN Financial Performance
Revenues and expenses
DESN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing DESN
AllUSDEURGBP
Fund name | Fund size | Fr. DESN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.10% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.10% |
iShares Healthcare Innovation£DRDR | £1B | 0.10% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.